TikoMed provides ILB and placebo substance for the study.

The study will include 120 patients from all over Norway and includes a randomized phase of 6 months where patients receive either ILB or riluzole followed by a 6-month open-label phase where patients receive both medications. Therefore, after the initial six-month period, all patients will receive ILB.

“We are very much looking forward to this groundbreaking study and we would like to strongly encourage all Norwegian ALS patients who qualify for the study to seek participation through their neurologist,” says Björn Pilström, CEO and Chief Medical Officer of TikoMed.